How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the company since its inception in 2009.

The structure-based drug discovery company raised the funds Oct. 14 from a syndicate that included crossover investors RA Capital and BVF Partners...